Aerovate Therapeutics (AVTE) Competitors $6.89 -0.30 (-4.17%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. IMNM, ZYME, AKBA, MLYS, TRVI, LENZ, NRIX, URGN, NUVB, and SIONShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Immunome (IMNM), Zymeworks (ZYME), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), Nurix Therapeutics (NRIX), Urogen Pharma (URGN), Nuvation Bio (NUVB), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Immunome Zymeworks Akebia Therapeutics Mineralys Therapeutics Trevi Therapeutics LENZ Therapeutics Nurix Therapeutics Urogen Pharma Nuvation Bio Sionna Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has stronger valuation & earnings, AVTE or IMNM? Aerovate Therapeutics has higher earnings, but lower revenue than Immunome. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.05Immunome$9.04M104.43-$292.96M-$3.18-3.41 Does the media prefer AVTE or IMNM? In the previous week, Immunome had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Immunome and 1 mentions for Aerovate Therapeutics. Immunome's average media sentiment score of 0.89 beat Aerovate Therapeutics' score of 0.00 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aerovate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AVTE or IMNM? Immunome has a consensus target price of $23.33, suggesting a potential upside of 115.05%. Given Immunome's stronger consensus rating and higher possible upside, analysts clearly believe Immunome is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in AVTE or IMNM? 44.6% of Immunome shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is AVTE or IMNM more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. Immunome's return on equity of -71.65% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Immunome -1,875.21%-71.65%-60.36% Which has more risk & volatility, AVTE or IMNM? Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. SummaryImmunome beats Aerovate Therapeutics on 10 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.71M$784.96M$5.59B$9.53BDividend YieldN/A4.84%4.71%4.14%P/E Ratio-2.301.3028.8923.88Price / SalesN/A25.05447.6498.82Price / CashN/A19.5635.6858.35Price / Book1.746.478.165.60Net Income-$75.52M-$4.35M$3.25B$265.26M7 Day Performance-11.10%-4.23%1.12%-0.15%1 Month Performance-38.15%-0.82%8.22%6.07%1 Year Performance-88.00%18.41%29.12%24.21% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-88.0%$199.71MN/A-2.3020News CoverageUpcoming EarningsHigh Trading VolumeIMNMImmunome1.9712 of 5 stars$10.84-0.3%$23.33+115.3%-12.2%$945.82M$10.94M-3.4140Upcoming EarningsZYMEZymeworks3.061 of 5 stars$13.46+1.0%$21.00+56.0%+25.4%$937.93M$93.38M-8.97460Upcoming EarningsAKBAAkebia Therapeutics3.712 of 5 stars$3.59+0.8%$6.75+88.0%+213.9%$934.98M$160.18M-17.09430MLYSMineralys Therapeutics2.5731 of 5 stars$13.60-5.0%$32.25+137.1%+20.2%$933.31MN/A-3.6528Upcoming EarningsTRVITrevi Therapeutics3.0083 of 5 stars$7.64-2.9%$20.88+173.2%+183.9%$923.10MN/A-16.9820Upcoming EarningsLENZLENZ Therapeutics1.6984 of 5 stars$31.51-0.3%$48.60+54.2%+36.8%$889.98MN/A-17.80110Earnings ReportUpcoming EarningsAnalyst RevisionGap UpNRIXNurix Therapeutics2.5074 of 5 stars$11.93+3.6%$29.31+145.7%-45.4%$880.69M$88.38M-4.57300URGNUrogen Pharma4.6396 of 5 stars$18.90-0.3%$32.86+73.8%+35.4%$875.52M$90.40M-5.94200Upcoming EarningsAnalyst ForecastNUVBNuvation Bio2.0288 of 5 stars$2.55+2.0%$7.17+181.0%-25.4%$867.67M$10.96M-1.0960Upcoming EarningsSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup Expiration Related Companies and Tools Related Companies Immunome Competitors Zymeworks Competitors Akebia Therapeutics Competitors Mineralys Therapeutics Competitors Trevi Therapeutics Competitors LENZ Therapeutics Competitors Nurix Therapeutics Competitors Urogen Pharma Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts